GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » Equity-to-Asset

NurExone Biologic (TSXV:NRX) Equity-to-Asset : 0.72 (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. NurExone Biologic's Total Stockholders Equity for the quarter that ended in Dec. 2024 was C$2.51 Mil. NurExone Biologic's Total Assets for the quarter that ended in Dec. 2024 was C$3.48 Mil.

The historical rank and industry rank for NurExone Biologic's Equity-to-Asset or its related term are showing as below:

TSXV:NRX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.09   Med: 0.57   Max: 0.75
Current: 0.72

During the past 4 years, the highest Equity to Asset Ratio of NurExone Biologic was 0.75. The lowest was 0.09. And the median was 0.57.

TSXV:NRX's Equity-to-Asset is ranked better than
56.25% of 1504 companies
in the Biotechnology industry
Industry Median: 0.67 vs TSXV:NRX: 0.72

NurExone Biologic Equity-to-Asset Historical Data

The historical data trend for NurExone Biologic's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Equity-to-Asset Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Equity-to-Asset
0.42 0.75 0.09 0.72

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.88 0.78 0.81 0.72

Competitive Comparison of NurExone Biologic's Equity-to-Asset

For the Biotechnology subindustry, NurExone Biologic's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NurExone Biologic's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's Equity-to-Asset falls into.


;
;

NurExone Biologic Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

NurExone Biologic's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )=Total Stockholders Equity/Total Assets
=2.509/3.478
=

NurExone Biologic's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )=Total Stockholders Equity/Total Assets
=2.509/3.478
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NurExone Biologic  (TSXV:NRX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


NurExone Biologic Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


NurExone Biologic Business Description

Traded in Other Exchanges
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.
Executives
James Angus Wilson (bilkstys-) Richardson 10% Security Holder, Director, Senior Officer

NurExone Biologic Headlines

No Headlines